Mutational Profile Evaluates Response and Survival to First-Line Chemotherapy in Lung Cancer.
NSCLC
SCLC
TMB
chemotherapy
lung cancer
subtype
Journal
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
ISSN: 2198-3844
Titre abrégé: Adv Sci (Weinh)
Pays: Germany
ID NLM: 101664569
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
25
08
2020
revised:
04
10
2020
entrez:
1
3
2021
pubmed:
2
3
2021
medline:
2
3
2021
Statut:
epublish
Résumé
Evaluating the therapeutic response and survival of lung cancer patients receiving first-line chemotherapy has always been difficult. Limited biomarkers for evaluation exist and as a result histology represents an empiric tool to guide therapeutic decision making. In this study, molecular signatures associated with response and long-term survival of lung cancer patients receiving first-line chemotherapy are discovered. Whole-exome sequencing is performed on pretherapeutic tissue samples of 186 patients [145 non-small cell lung cancer (NSCLC) and 41 small cell lung cancer (SCLC)]. On the basis of genomic alteration characteristics, NSCLC patients can be classified into four subtypes (C1-C4). The long-term survival is similar among different subtypes. SCLC patients are also divided into four subtypes and significant difference in their progression free survival is revealed (
Identifiants
pubmed: 33643802
doi: 10.1002/advs.202003263
pii: ADVS2192
pmc: PMC7887584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2003263Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2020 The Authors. Advanced Science published by Wiley‐VCH GmbH.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Cancer Sci. 2019 Jun;110(6):2014-2021
pubmed: 31033100
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
Genome Med. 2017 Apr 19;9(1):34
pubmed: 28420421
JAMA Oncol. 2019 Jul 18;:
pubmed: 31318407
Cancer Med. 2019 Jul;8(8):4055-4069
pubmed: 31150167
J Thorac Oncol. 2018 Mar;13(3):323-358
pubmed: 29396253
Int J Chron Obstruct Pulmon Dis. 2018 Jul 12;13:2139-2146
pubmed: 30034229
Expert Opin Biol Ther. 2013 Oct;13(10):1401-12
pubmed: 23930754
J Natl Compr Canc Netw. 2018 Jul;16(7):807-821
pubmed: 30006423
EBioMedicine. 2019 Apr;42:304-310
pubmed: 30878600
Science. 2018 Sep 7;361(6406):1033-1037
pubmed: 30190408
Lancet. 2016 Sep 3;388(10048):1012-24
pubmed: 27598681
Oncologist. 2019 Nov;24(11):e1070-e1081
pubmed: 30902917
Nat Rev Cancer. 2017 Oct 25;17(11):637-658
pubmed: 29068003
J Clin Oncol. 2008 Jul 20;26(21):3543-51
pubmed: 18506025
Nat Methods. 2018 Jan;15(1):61-66
pubmed: 29200198
Genome Biol. 2016 Feb 22;17:31
pubmed: 26899170
Clin Cancer Res. 2019 Aug 1;25(15):4712-4722
pubmed: 31028088
JAMA. 2019 Apr 9;321(14):1391-1399
pubmed: 30964529
J Cancer. 2019 Jun 9;10(15):3553-3559
pubmed: 31293660
Cancer Med. 2019 Apr;8(4):1434-1441
pubmed: 30762300